AIMGEL TECHNOLOGY
We coat and load surface and soluble biological signals on hydrogel microparticles.
We can control the diverse signals proximal to the cells to promote activation, expansion and differentiation into therapeutics. AimGel technology enables us to generate a broad pipeline of product candidates for different cell types and diseases.
We can control the diverse signals proximal to the cells to promote activation, expansion and differentiation into therapeutics. AimGel technology enables us to generate a broad pipeline of product candidates for different cell types and diseases.
> Cell-mimicking features
|
AimGel is a biomimetic microcarrier-based cell culture technology. "AimGel looks like a cell. But, it does not multiply, change identity or die. It consists of necessary and sufficient components to support precursor cells to grow and mature into therapeutics." AimGel gives users control over the surface and soluble signals exposed to the precursor cells while preserving the performance of cell culture.
|
|
|
How it works
|
How it benefits
|
> Modular design & rapid customization
Different cells therapeutics require different surface and soluble signals cocktails and protocols for manufacturing. To meet the diverse demands, we compartmentalize AimGel into four basic components: hydrogel core, lipid shell, surface and soluble factors. This divide and conquer strategy allows easy and rapid customization of AimGel design and manufacturing, giving us adaptive advantage to meet the needs of different cell therapies and diseases while providing all-round effective signals.
> Scalable & ready-to-use
AimGel is designed to be used "straight-out-from-the-bottle" in both lab research and clinical manufacturing settings. It aims to serve as a platform for the standardization of culture process. AimGel's modular approach and streamlined assembly process of the signaling components into one unified cell-mimicking package can give better quality control over the productions of AimGel products. With AimGel technology, we enable and empower more scalable, rapid and cost-efficient generation of cell therapies.
Reduced COGS
|
Standardized production
|
Faster manufacturing
|
Publications and presentations
- Lau, C. M. L., Chung, J. T., Chau Y. (2022) Artificial antigen presenting cells for ex vivo T cell growth and differentiation. AIChE 4th Cell Therapies and Immunotherapy Conference
- Chung, J. T., Lau, C. M. L., Chau, Y. (2022) Self-adjuvanted polysaccharide-based nanogels for intracellular antigenic protein delivery in dendritic cell vaccines. AIChE 4th Cell Therapies and Immunotherapy Conference
- Chung, J. T., Lau, C. M. L., Chau, Y. (2022) The synthesis of dextran derivative-hydrogels with various surface charge and the immunomodulatory effects in vitro. 16th Annual Meeting RSC Biomaterials Chemistry
- Chung, J. T., Lau, C. M. L., & Chau, Y. (2021). A dual-modular polysaccharide-based hydrogel platform with controlled release of biological cues for dendritic cells priming. CRS Annual Meeting Conference Paper.
- Chung, J. T., Lau, C. M. L., Chau, Y. (2021). The effect of polysaccharide-based hydrogel on the response of antigen presenting cell line to immunomodulators. Biomater. Sci. https://doi.org/10.1039/D1BM00854D
- Chung, C. H. Y., Lau, C. M. L., Sin, D. T., Chung, J. T., Zhang, Y., Chau, Y., Yao, S. (2021). Droplet-Based Microfluidic Synthesis of Hydrogel Microparticles via Click Chemistry-Based Cross-Linking for the Controlled Release of Proteins. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.1c00509
- Lau, C. M. L., Jahanmir, G., Yu, Y., & Chau, Y. (2021). Controllable multi-phase protein release from in-situ hydrolyzable hydrogel. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2021.05.006
Allegrow Biotech. |
|
Disclaimer Impressum Credits Cookie Policy Privacy Statement
© 2023 Allegrow Biotech Ltd. All Rights Reserved.